These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 31765822)

  • 41. Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease.
    Brys I; Nunes J; Fuentes R
    Eur J Neurosci; 2017 Aug; 46(3):1906-1917. PubMed ID: 28370471
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit.
    Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P
    Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopamine and α-synuclein dysfunction in Smad3 null mice.
    Tapia-González S; Giráldez-Pérez RM; Cuartero MI; Casarejos MJ; Mena MÁ; Wang XF; Sánchez-Capelo A
    Mol Neurodegener; 2011 Oct; 6():72. PubMed ID: 21995845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
    Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
    Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.
    Schepici G; Silvestro S; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The D3 dopamine receptor: From structural interactions to function.
    Fiorentini C; Savoia P; Bono F; Tallarico P; Missale C
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1462-9. PubMed ID: 25532864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
    Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
    J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease.
    Brockhausen I; Schutzbach J; Wang J; Fishwick B; Brockhausen J
    Glycoconj J; 2022 Feb; 39(1):55-74. PubMed ID: 34757539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS.
    Miller KM; Patterson JR; Kochmanski J; Kemp CJ; Stoll AC; Onyekpe CU; Cole-Strauss A; Steece-Collier K; Howe JW; Luk KC; Sortwell CE
    J Neurosci; 2021 Mar; 41(9):2039-2052. PubMed ID: 33472823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase.
    Kang SS; Wu Z; Liu X; Edgington-Mitchell L; Ye K
    Neurotherapeutics; 2022 Jul; 19(4):1283-1297. PubMed ID: 35595958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impairment of Macroautophagy in Dopamine Neurons Has Opposing Effects on Parkinsonian Pathology and Behavior.
    Hunn BHM; Vingill S; Threlfell S; Alegre-Abarrategui J; Magdelyns M; Deltheil T; Bengoa-Vergniory N; Oliver PL; Cioroch M; Doig NM; Bannerman DM; Cragg SJ; Wade-Martins R
    Cell Rep; 2019 Oct; 29(4):920-931.e7. PubMed ID: 31644913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.
    Yu Z; Xu X; Xiang Z; Zhou J; Zhang Z; Hu C; He C
    PLoS One; 2010 Apr; 5(4):e9956. PubMed ID: 20386702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.
    Fuxe K; Guidolin D; Agnati LF; Borroto-Escuela DO
    Expert Opin Ther Targets; 2015 Mar; 19(3):377-98. PubMed ID: 25486101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modulation of alpha-synuclein aggregation by dopamine: a review.
    Leong SL; Cappai R; Barnham KJ; Pham CL
    Neurochem Res; 2009 Oct; 34(10):1838-46. PubMed ID: 19444607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
    Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
    Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease.
    Favier M; Carcenac C; Drui G; Vachez Y; Boulet S; Savasta M; Carnicella S
    Sci Rep; 2017 Jan; 7():41589. PubMed ID: 28134302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.